130727-21-8
Chemical Structure
JO146
- CAS No.: 130727-21-8
- Formula:C31H44N3O7P
- Molecular Weight:601.67
IUPAC Name: (S)-N-methyl-1-(1-methylpiperidin-3-yl)methanamine
InChIKey: FOEQHKOSOICMEF-QIELNMHASA-N
SMILES: O=C(OC(C)(C)C)N[C@@H](C(C)C)C(N1[C@H](C(NC(P(OC2=CC=CC=C2)(OC3=CC=CC=C3)=O)C(C)C)=O)CCC1)=O
Biological Activity: JO146 is an anti-chlamydial agent, Antibacterial agent, and CtHtrA serine protease inhibitor, with an IC50 of 21.86 μM against CtHtrA serine protease. JO146 alters the morphology of chlamydial cells, reduces inclusion vacuoles, decreases the number of infectious progeny, and eliminates viable Chlamydia trachomatis under stress or conditions that reverse persistent infection. JO146 shows no activity against Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus, but exhibits bactericidal activity against Helicobacter pylori. JO146 can be used in research related to Chlamydia trachomatis infection, chlamydial infection in cattle and sheep, and Helicobacter pylori infection[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
JO146 | 98.49% | JO146 is an anti-chlamydial agent, Antibacterial agent, and CtHtrA serine protease inhibitor, with an IC50 of 21.86 μM against CtHtrA serine protease. JO146 alters the morphology of chlamydial cells, reduces inclusion vacuoles, decreases the number of infectious progeny, and eliminates viable Chlamydia trachomatis under stress or conditions that reverse persistent infection. JO146 shows no activity against Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus, but exhibits bactericidal activity against Helicobacter pylori. JO146 can be used in research related to Chlamydia trachomatis infection, chlamydial infection in cattle and sheep, and Helicobacter pylori infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Hwang J, et al. Design, synthesis and biological evaluation of P2-modified proline analogues targeting the HtrA serine protease in Chlamydia. European journal of medicinal chemistry. 2022 Feb 15;230:114064. [Content Brief]
- [2]. Ong VA, et al. The protease inhibitor JO146 demonstrates a critical role for CtHtrA for Chlamydia trachomatis reversion from penicillin persistence. Frontiers in cellular and infection microbiology. 2013;3:100. [Content Brief]
- [3]. Ong VA, et al. In vitro susceptibility of recent Chlamydia trachomatis clinical isolates to the CtHtrA inhibitor JO146. Microbes and infection. 2015;17(11-12):738-44. [Content Brief]
- [4]. Hwang J, et al. Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against Helicobacter pylori: A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles. Pharmaceutics. 2022 Feb 1;14(2):348. [Content Brief]
Keywords
